IMMUNE THROMBOCYTOPENIA

This study is testing a new antibody drug called Anti-CD38 for children aged 6 and up with immune thrombocytopenia (ITP), a condition that causes low platelet counts and bleeding risk. The trial is for kids who haven't gotten better or who relapsed after standard treatments. Rese…

This study is testing whether a drug called daratumumab works better than rituximab for children with immune thrombocytopenia (ITP), a condition that causes low platelet counts and bleeding risk. The trial is for children aged 6-18 whose ITP didn't improve or came back after stan…

This study is testing whether combining two existing drugs, rituximab and daratumumab, can help adults with a hard-to-treat form of immune thrombocytopenia (ITP). ITP is a condition where the immune system mistakenly attacks platelets, causing a risk of easy bruising and bleeding…

This study is testing whether adding a second drug (anti-CD38) to a standard treatment (rituximab) works better for adults with immune thrombocytopenia (ITP) whose platelet counts stayed low after steroid therapy. Researchers will compare the safety and effectiveness of the two-d…

This study is testing whether a drug called Daratumumab works better than the standard drug Rituximab for adults with immune thrombocytopenia (ITP), a condition that causes low platelets and bleeding risk. It's for people whose ITP didn't get better or came back after initial ste…

This study is testing an oral medication called rilzabrutinib for adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, increasing bleeding risk. It's for people whose first treatment didn't work well or stopped working. The main goal i…

This is the first study in people to test a new drug called SHR-2173 for adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing a risk of bleeding. The main goal is to check if the injection is safe and well-tolerated. Researcher…

This early-stage study is testing a new cell therapy called PRG-1801 for adults with immune thrombocytopenia (ITP) that has come back or hasn't responded to standard treatments. The main goal is to find a safe dose and see if the therapy helps increase platelet counts. Researcher…

This study is testing an investigational drug called tafasitamab in adults with primary autoimmune blood cell disorders, specifically immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). The main goals are to see if the drug is safe and if it can help raise…

This study is testing whether a specific lab test that looks for antibodies against a person's own platelets can help doctors diagnose immune thrombocytopenia (ITP) faster and more accurately. It will enroll 225 adults who have been found to have low platelet counts. The goal is …

This study is creating a national registry to track 1500 adult patients in France who have immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA). The goal is to understand how these rare blood disorders progress in real life and see how well current treatments work …